PT3038622T - Compostos heterocíclicos e métodos de utilização - Google Patents

Compostos heterocíclicos e métodos de utilização

Info

Publication number
PT3038622T
PT3038622T PT148392137T PT14839213T PT3038622T PT 3038622 T PT3038622 T PT 3038622T PT 148392137 T PT148392137 T PT 148392137T PT 14839213 T PT14839213 T PT 14839213T PT 3038622 T PT3038622 T PT 3038622T
Authority
PT
Portugal
Prior art keywords
methods
heterocyclic compounds
heterocyclic
compounds
Prior art date
Application number
PT148392137T
Other languages
English (en)
Inventor
Chakravarty Sarvajit
Rai Roopa
Minh Pham Son
Pujala Brahmam
Jangir Ramniwas
Guguloth Rambabu
Kumar Sharma Vijay
Original Assignee
Medivation Tech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivation Tech Llc filed Critical Medivation Tech Llc
Publication of PT3038622T publication Critical patent/PT3038622T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT148392137T 2013-08-28 2014-08-28 Compostos heterocíclicos e métodos de utilização PT3038622T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2816MU2013 2013-08-28
IN3497MU2013 2013-11-04

Publications (1)

Publication Number Publication Date
PT3038622T true PT3038622T (pt) 2018-07-13

Family

ID=52584081

Family Applications (1)

Application Number Title Priority Date Filing Date
PT148392137T PT3038622T (pt) 2013-08-28 2014-08-28 Compostos heterocíclicos e métodos de utilização

Country Status (28)

Country Link
US (1) US9670172B2 (pt)
EP (1) EP3038622B1 (pt)
JP (2) JP2017506618A (pt)
KR (1) KR20160067841A (pt)
CN (1) CN106029072A (pt)
AU (1) AU2014312245B2 (pt)
CA (1) CA2922346A1 (pt)
CR (1) CR20160136A (pt)
DK (1) DK3038622T3 (pt)
EC (1) ECSP16012582A (pt)
ES (1) ES2676585T3 (pt)
HR (1) HRP20181017T1 (pt)
HU (1) HUE039624T2 (pt)
IL (1) IL244268A0 (pt)
LT (1) LT3038622T (pt)
MX (1) MX2016002443A (pt)
NO (1) NO20160470A1 (pt)
PH (1) PH12016500382A1 (pt)
PL (1) PL3038622T3 (pt)
PT (1) PT3038622T (pt)
RS (1) RS57338B1 (pt)
RU (1) RU2016111138A (pt)
SA (1) SA516370641B1 (pt)
SG (2) SG10201806370QA (pt)
SI (1) SI3038622T1 (pt)
TR (1) TR201809185T4 (pt)
UA (1) UA116675C2 (pt)
WO (1) WO2015031650A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073826A1 (en) 2014-11-07 2016-05-12 Fgh Biotech, Inc. Synthesis of fatostatin based polycyclic compounds
EP3237413A4 (en) 2014-12-23 2018-09-12 FGH Biotech Compositions of fatostatin based heterocyclic compounds and uses thereof
CA2977539A1 (en) 2015-03-04 2016-09-09 Medivation Technologies, Inc. Sterol regulatory element-binding proteins (srebps) inhibitors
EP3265088A1 (en) * 2015-03-04 2018-01-10 Medivation Technologies LLC Srebp blockers for use in treating liver fibrosis, elevated cholesterol and insulin resistance
CN105732355A (zh) * 2016-04-07 2016-07-06 戊言医药科技(上海)有限公司 1-(5-氟-2-碘苯基)乙酮的制备方法
KR102498741B1 (ko) 2016-04-29 2023-02-10 에프지에이치 바이오테크 인코포레이티드 질환 치료용 이-치환된 피라졸 화합물
CN110072861B (zh) * 2016-09-07 2022-11-11 Fgh生物科技公司 用于治疗疾病的二取代吡唑类化合物
EP3676264A1 (en) * 2017-08-28 2020-07-08 Acurastem Inc. Pikfyve kinase inhibitors
AU2019212959A1 (en) 2018-01-29 2020-09-17 Capulus Therapeutics, Llc SREBP inhibitors comprising a 6-membered central ring
WO2020132700A1 (en) 2018-12-21 2020-06-25 Fgh Biotech Inc. Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
EP4096659A4 (en) * 2020-01-27 2023-10-18 Capulus Therapeutics, LLC SREBP INHIBITORS COMPRISING A THIOPHENIC RING
CN116041277A (zh) * 2023-01-18 2023-05-02 中国药科大学 苯基和联苯基取代的五元杂环类化合物及其制备方法、药物组合物和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3796764B2 (ja) * 1995-01-25 2006-07-12 コニカミノルタホールディングス株式会社 金属錯体化合物及び該化合物を用いた光記録媒体
US6291514B1 (en) * 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
NZ506507A (en) 1998-02-09 2003-08-29 Dimensional Pharm Inc Heteroaryl amidine, methylamidine or guanidine derivatives useful as urokinase inhibitors
JP2002517479A (ja) * 1998-06-09 2002-06-18 ザ・ユニバ−シティ・オブ・コネチカット 鎮痛薬としてのアナンダミド輸送体阻害剤
ES2243337T3 (es) 1999-12-16 2005-12-01 Schering Corporation Imidazoles sustituidos antagonistas del receptor y5 del neuropeptido y.
AR029686A1 (es) 2000-06-22 2003-07-10 Dow Agrosciences Llc Compuestos de 2-(3,5-disustituido-4-piridil)-4-(tienilo, tiazolilo o arilfenil)-1,3-oxazolina, composiciones y metodos para el control de insectos o acaros y/o plantas utilizando dichos compuestos
CN102584813B (zh) 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
NZ565460A (en) 2005-07-26 2011-06-30 Bial Portela & Ca Sa Nitrocatechol derivatives as COMT inhibitors
EP1922068A4 (en) 2005-08-16 2010-08-11 Icagen Inc INHIBITORS OF VOLTAGE-CONTROLLED SODIUM CHANNELS
US8229106B2 (en) 2007-01-22 2012-07-24 D.S.P. Group, Ltd. Apparatus and methods for enhancement of speech
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
US9212179B2 (en) 2007-02-02 2015-12-15 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US8207196B2 (en) * 2007-02-02 2012-06-26 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
EP2379513A1 (en) * 2008-12-30 2011-10-26 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as raf kinase inhibitors
US8242260B2 (en) * 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
WO2011085269A1 (en) * 2010-01-08 2011-07-14 Selexagen Therapeutics, Inc. Raf kinase inhibitors
WO2012084678A1 (en) 2010-12-23 2012-06-28 Syngenta Participations Ag Novel imidazoles useful as plant fungicides
GB201116017D0 (en) 2011-09-16 2011-10-26 Univ Surrey Bi-aromatic and tri-aromatic compounds as nadph oxidase inhibitors
EP2793879A4 (en) 2011-12-23 2015-07-01 Millennium Pharm Inc HETEROARYLE AND USES THEREOF
WO2014199164A1 (en) 2013-06-12 2014-12-18 Ampla Pharmaceuticals, Inc. Diaryl substituted heteroaromatic compounds
AU2014302313A1 (en) 2013-06-26 2016-02-18 Baylor College Of Medicine Rett syndrome and treatments therefore

Also Published As

Publication number Publication date
SG11201601486TA (en) 2016-03-30
HRP20181017T1 (hr) 2018-08-24
EP3038622A1 (en) 2016-07-06
CA2922346A1 (en) 2015-03-05
RS57338B1 (sr) 2018-08-31
HUE039624T2 (hu) 2019-01-28
AU2014312245B2 (en) 2018-12-13
EP3038622A4 (en) 2017-04-12
KR20160067841A (ko) 2016-06-14
NO20160470A1 (en) 2016-03-18
DK3038622T3 (en) 2018-07-16
IL244268A0 (en) 2016-04-21
PH12016500382A1 (en) 2016-05-16
CN106029072A (zh) 2016-10-12
TR201809185T4 (tr) 2018-07-23
RU2016111138A3 (pt) 2018-06-27
SG10201806370QA (en) 2018-08-30
MX2016002443A (es) 2016-12-16
CR20160136A (es) 2016-08-04
JP2019089854A (ja) 2019-06-13
SA516370641B1 (ar) 2018-05-21
SI3038622T1 (en) 2018-08-31
UA116675C2 (uk) 2018-04-25
ECSP16012582A (es) 2018-09-30
US9670172B2 (en) 2017-06-06
JP2017506618A (ja) 2017-03-09
WO2015031650A1 (en) 2015-03-05
PL3038622T3 (pl) 2018-09-28
RU2016111138A (ru) 2017-10-04
ES2676585T3 (es) 2018-07-23
EP3038622B1 (en) 2018-05-30
AU2014312245A1 (en) 2016-04-07
US20150065519A1 (en) 2015-03-05
LT3038622T (lt) 2018-07-25

Similar Documents

Publication Publication Date Title
HRP20181392T1 (hr) Heterociklični spojevi i njihova uporaba
HK1223351A1 (zh) 嘧啶衍生物作為激酶抑制劑
ZA201602220B (en) Heterocyclic compounds and uses thereof
HK1217428A1 (zh) 取代的苯並噁唑及其使用方法
SG11201600028YA (en) Substituted aminopyrimidine compounds and methods of use
HK1218512A1 (zh) 雜環化合物和其用途
IL244268A0 (en) Heterocyclic compounds and methods of use
EP2938341A4 (en) Heterocyclic compounds and methods for the use thereof
PL3019477T3 (pl) Związki heterocykliczne i sposoby ich stosowania
HK1220363A1 (zh) 雜環化合物及其用途